Full text is available at the source.
Abstract
Delayed gastric emptying is a critical factor in the effectiveness of levodopa treatment for Parkinson's disease.
- Glucagon-like peptide-1 (GLP-1) receptor agonists may inhibit gastric motility, affecting drug absorption.
- Parkinson's disease is associated with gastrointestinal dysfunction that can further delay gastric emptying.
- The interaction between PD-related gastric issues and GLP-1 signaling may worsen the delivery of dopaminergic medications.
- A conceptual model suggests a 'double-hit' effect where both conditions exacerbate the challenges of managing PD symptoms.
- This relationship highlights a potential trade-off between the benefits of GLP-1 receptor agonists and their negative impact on levodopa efficacy.
Simplified